Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry
Authors:
- Wilfredo López-OjedaWLWilfredo López-Ojeda
- Robin A. HurleyRHRobin A. Hurley
- 1 April 2024
- journal article
- research article
- Published by American Psychiatric Association Publishing in The Journal of Neuropsychiatry and Clinical Neurosciences
- Vol. 36 (2) , A4-86
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s diseaseAgeing Research Reviews, 2023
- The effect of glucagon like peptide-1 receptor agonist on behavioral despair and anxiety-like behavior in ovariectomized rats: Modulation of BDNF/CREB, Nrf2 and lipocalin 2Behavioural Brain Research, 2022
- Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative ReviewPharmaceutical Research, 2022
- The Brain’s Reward System in Health and Disease2021
- Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeuticsBiochemical Pharmacology, 2020
- A novel mouse model of glucagon‐like peptide‐1 receptor expression: A look at the brainJournal of Comparative Neurology, 2020
- Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1Brain Research, 2020
- Antipsychotic drugs: challenges and future directionsWorld Psychiatry, 2018
- Improving Current Treatments for SchizophreniaDrug Development Research, 2016
- Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous systemJournal of Comparative Neurology, 1998